

For consultation and local adaptation

- A **Helicobacter test & treat strategies will benefit patients with ulcer disease, 8% of patients with functional dyspepsia, and reduce future risk of ulcer disease, gastric cancer and risks of long-term PPIs.^{1,2}**
- A **In patients aged 55 years and older, with new unexplained and persistent (over 4-6 weeks) recent onset dyspepsia, an urgent referral for endoscopy should be made.^{3,4}**


WHO TO TEST AND TREAT FOR HELICOBACTER⁵⁻⁷

- A Patients with uncomplicated dyspepsia unresponsive to lifestyle change, antacids, H₂A or 1 month PPI⁷⁻¹⁰ and without alarm symptoms (for definitions - see references 12 and 13)^{7,11,12}
- Routine testing is **not** recommended in patients with Gastro-Oesophageal Reflux Disease.
- Patients with a past history of gastric ulcer (GU) or duodenal ulcer (DU) who have not previously been tested.
- In chronic NSAID user without ulcer history, HP eradication will reduce peptic ulcers and/or bleeding but will not remove all risk.

WHICH NON-INVASIVE HELICOBACTER TEST IS UNCOMPLICATED DYSPEPSIA¹³

- A **Urea breath test (UBT)^{14,15}** Detects current infection (Prescription-based high cost test)
Most accurate pre and post treatment test (sens & spec 95%)
By prescription (BNF 1.3.1)¹⁶
 - A **Stool helicobacter antigen test** detects current infection.¹⁷ (Medium cost). Pea-sized piece of stool to local lab (check availability of test). (sens & spec 97%)
 - A **Blood serology** in plain bottle.⁵ (Low cost)
Detects antibody to helicobacter and does not differentiate active from past infection. Therefore less accurate than UBT or stool test (sens 85-92%, spec 79-83%)^{19,20} **DO NOT** use in elderly, children or post treatment.^{21,22}
 - A Useful when other tests may be negative Eg in patients with acute GI bleed or on antibiotics.
Near patient serology tests are not as accurate.¹⁵ **DO NOT USE**
- DO NOT perform UBT or stool antigen test within 2 weeks of PPI or 4 weeks of antibiotics as these drugs suppress bacteria and may lead to false negative^{17,18}
- Note: A 100% sensitive (sens) test correctly identifies all patients with helicobacter. A 100% specific (spec) test correctly identifies all patients without helicobacter

WHAT TO DO WITH HELICOBACTER RESULT



TREATMENT REGIMENS

Do not use clarithromycin or metronidazole if used in the past year for ANY infection

| First line ^{A+} 7 days BD | Second-line regimens ^{A+} 14 days | Alternative 3 rd line antibiotics on advice of microbiologist or gastroenterologist |
|---|---|--|
| lansoprazole 30mg (or other PPI) PLUS clarithromycin 250mg with metronidazole 400mg OR clarithromycin 500mg with amoxicillin 1g | PPI BD PLUS tripotassium dicitratobismuthate 240mg BD OR ranitidine bismuth citrate 400mg BD PLUS 2 antibiotics not previously used: amoxicillin 1g BD clarithromycin ^{A+} 500mg BD metronidazole 400mg BD tetracycline hydrochloride 500mg QDS | levofloxacin 250 mg BD rifabutin 300mg OD furazolidine 200mg BD |

WHEN TO RETEST FOR HELICOBACTER

- D To reassure patients of eradication
 - D Patients with complicated peptic ulcer or MALTOMA
 - Breath test is the most accurate^{A-}
 - Stool antigen test is an alternative^{A-}
 - DO NOT use serology^{A-}
- Wait 4 weeks after treatment

WHEN TO REFER FOR HELICOBACTER CULTURE & SUSCEPTIBILITY TESTING AT ENDOSCOPY²⁵

- D Patients who have had metronidazole & clarithromycin for any infection & are allergic to one of the other antibiotics
 - Patients who have received two courses of antibiotic treatment and are still helicobacter positive
- For advice on antral biopsy specimens and Dent's transport medium, contact the HPA Centre for Infections, London.²⁵

KEY A B C D Indicates grade of recommendation

References

1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. The European Helicobacter Study Group (EHSg). Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut* 2007;**56**:772-81.
2. Shah R. BMJ Masterclass for GPs. Dyspepsia and *Helicobacter pylori*. *BMJ* 2007;**334**:41-3.
3. NICE Clinical Guideline no. 27: Referral guidelines for suspected cancer. June 2005. <http://www.nice.org.uk/guidance/index.jsp?action=byID&r=true&o=10968> (Accessed 21st April 2008)
4. NICE Clinical Guideline no. 17: Dyspepsia – management of dyspepsia in adults in primary care. Quick reference guide. August 2004 amended June 2005. <http://www.nice.org.uk/guidance/index.jsp?action=download&o=29458> (Accessed 21st April 2008)
5. Jones R, Tait C, Sladen G, Weston-Baker J. A trial of a test and treat strategy for *Helicobacter pylori* positive dyspeptic patients in general practice. *Int J Clin Pract* 1999;**53**:413-6. *Non-invasive testing for H. pylori is as effective as endoscopy in determining the management of dyspepsia.*
6. McColl KE, Murray LS, Gillen D, Walker A, Wirz A, Fletcher J *et al.* Randomised trial of endoscopy with testing for *Helicobacter pylori* compared with non-invasive *H. pylori* testing alone in the management of dyspepsia. *BMJ* 2002;**324**:999-1002. *Non-invasive testing for H. pylori is as effective as endoscopy in determining the management of dyspepsia.*
7. Delaney BC, Qume M, Moayyedi P, Logan RFA, Ford AC, Elliott C, McNulty C, Wilson S, Hobbs FDR. *Helicobacter pylori* test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). *BMJ* 2008;**336**:651-4. *Test and treat and acid suppression are equally cost-effective in the initial management of dyspepsia. Empirical acid suppression is an appropriate initial strategy. As costs are similar overall, general practitioners should discuss with patients at which point to consider H. pylori testing.*
8. Ofman JJ, Rabeneck L. The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review. *Am J Med* 1999;**106**:335-46. *This systematic review found no evidence that an initial course of empirical therapy rather than endoscopy adversely affects outcome.*
9. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. *Helicobacter pylori* test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. *Lancet* 2000;**356**:455-60. *Test and treat policy in over 55 year olds was as safe as in under 55 year olds.*
10. Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating *Helicobacter pylori* infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-*Helicobacter pylori* positive (CADET-Hp) randomised controlled trial. *BMJ* 2002;**324**:1012-6. *Canadian 294 HP positive primary care test and treat study of 18-82 year olds with dyspepsia.*
11. American Gastroenterological Association medical position statement: evaluation of dyspepsia. *Gastroenterology* 1998;**114**:579-81. *Patients of any age with dysphagia, recurrent vomiting, significant unintentional weight loss, anaemia from GIT haemorrhage or upper abdominal mass should have early investigation.*
12. Department of Health. Referral Guidelines for suspected cancer. London: The Department; 2000 [cited 26th August 2002]. Available from http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4008746 (Accessed 21.04.08) *Urgent referral is indicated for significant gastrointestinal bleeding, dysphagia, unintentional weight loss, epigastric loss, suspicious barium meal. Urgent referral is indicated for 55 and over with iron deficiency, anaemia, persistent vomiting.*
13. Vakil N. Review article: The cost of diagnosing *Helicobacter pylori* infection. *Alimentary Pharmacology & Therapeutics* 2001;**15** (Suppl 1):10-15. *Review describing the different tests available and their accuracy at different prevalence rates.*
14. Klein PD, Malaty HM, Martin RF, Graham KS, Genta RM, Graham DY. Noninvasive detection of *Helicobacter pylori* infection in clinical practice: the 13C urea breath test. *Am J Gastroenterol* 1996;**9**:690-4. *RCT showing urea breath tests are very accurate.*
15. Vaira D, Vakil N. Blood, urine, stool, breath, money, and *Helicobacter pylori*. *GUT* 2001;**48**:287-9. *Data from 8 studies of near patient serology tests show sensitivity 71.5% and specificity 87.6% and urea breath test has 95% specificity and sensitivity.*
16. British National Formulary No. 55 <http://www.bnf.org/bnf/bnf/current/73336.htm#this> (Accessed 21st April 2008)

17. Gisbert JP, de la Morena F, Abaira V. Accuracy of monoclonal stool antigen test for the diagnosis of *H. pylori* infection: A systematic review and meta-analysis. *Am J Gastroenterol* 2006;**101**:1921-30. *Review of 22 studies showed HP stool antigen test had sensitivity 94% and specificity 97%. Post treatment – sensitivity 93%, specificity 96%.*
18. El-Nujumi A, Halditch TE, Williams C, McColl KE. Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test. *Eur J Gastroenterol Hepatol* 1998;**10**:759-64. *Concurrent use of PPIs or antibiotics led to false negative UBT results.*
19. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for *Helicobacter pylori* infection differ in accuracy? A meta-analysis. *Am J Gastroenterol* 1996;**91**:1138-44. *Meta-analysis of 21 laboratory based serology kits – sensitivity 85% specificity 79%.*
20. Laheij RJ, Straatman H, Jansen JB, Verbeek AL. Evaluation of commercially available *Helicobacter pylori* serology kits: a review. *J Clin Microbiol* 1998;**36**:2803-9. *A comparison of 36 laboratory based serology kits – median sensitivity 92% and specificity 83%.*
21. Bazzoli F, Zagari RM, Pozzato P. *et al* . *Helicobacter pylori*: Optimum diagnosis and test of cure. *J Chemother* 1999;**11**:601-605.
22. Burette A. How and when to test or retest for *H. pylori*. *Acta Gastro-Enterologica Belgica* 1998;**61**:336-343.
23. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, Delaney B. Systematic review and economic evaluation of *Helicobacter pylori* eradication treatment for non-ulcer dyspepsia. *BMJ* 2000;**321**:649-64. *This is a systematic review of economic evaluation of HP eradication in non-ulcer dyspepsia. The mean response rate to treatment in HP positive NUD patients is 36% and the mean placebo response rate is 28%.*
24. Gene E, Calvet X, Azagra R. Diagnosis of *Helicobacter pylori* after triple therapy in uncomplicated duodenal ulcer: a cost-effective analysis. *Aliment Pharmacol Ther* 2000;**14**:433-42. *Comparison of different follow-up strategies post treatment – in patients with uncomplicated DU (and therefore we may assume NUD) testing for eradication after HP treatment markedly increases cost with no clear improvement in results).*
25. Diagnostic and Specialist Identification Unit, Gastrointestinal, Emerging and Zoonotic Infections, Health Protection Agency Centre for Infections, , 61 Colindale Avenue, Colindale, London NW9 5EQ Tel: 020 8327 6114.
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947328906

We welcome, in fact encourage, opinions on the advice given and future topics we should cover. We would be most appreciative if you could email any evidence or references that support your requests for change so that we may consider them at our annual review.

Comments should be submitted to Dr Cliodna McNulty, Head, HPA Primary Care Unit, Microbiology Laboratory, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN.

Email: cliodna.mcnulty@hpa.org.uk or jill.whiting@hpa.org.uk